{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:41:23Z","timestamp":1760013683933},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T00:00:00Z","timestamp":1551916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Prolyl-hydroxylase (PHD) inhibitors (PHD-I) are the most appealing drugs undergoing clinical development for the treatment of anaemia in patients with chronic kidney disease. PHD inhibition mimics the exposure of the body to hypoxia and activates the hypoxia-inducible factor system. Among many other pathways, this activation promotes the production of endogenous erythropoietin (EPO) and the absorption and mobilization of iron. PHD-I are given orally and, differing from erythropoiesis-stimulating agents (ESAs), they correct and maintain haemoglobin levels by stimulating endogenous EPO production. Their efficacy and safety are supported by several Phases I and II studies with relatively short follow-up. This class of drugs has the potential to have a better safety profile than ESAs and there may be additional advantages for cardiovascular disease (CVD), osteoporosis and metabolism. However, possible adverse outcomes are feared. These span from the worsening or occurrence of new cancer, to eye complications or pulmonary hypertension. The data from the ongoing Phase III studies are awaited to better clarify the long-term safety and possible advantages of PHD-I.<\/jats:p>","DOI":"10.1093\/ndt\/gfz031","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T15:56:57Z","timestamp":1548345417000},"page":"926-932","source":"Crossref","is-referenced-by-count":7,"title":["Are prolyl-hydroxylase inhibitors potential alternative treatments for anaemia in patients with chronic kidney disease?"],"prefix":"10.1093","volume":"35","author":[{"given":"Francesco","family":"Locatelli","sequence":"first","affiliation":[{"name":"Department of Nephrology and Dialysis, Alessandro Manzoni Hospital ASST-Lecco, Lecco, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Del Vecchio","sequence":"first","affiliation":[{"name":"Department of Nephrology and Dialysis, Alessandro Manzoni Hospital ASST-Lecco, Lecco, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,3,7]]},"reference":[{"key":"2020061010444475100_gfz031-B1","first-page":"279","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2020061010444475100_gfz031-B2","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ndt\/gft033","article-title":"Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement","volume":"28","author":"Locatelli","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2020061010444475100_gfz031-B3","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","article-title":"Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension","volume":"92","author":"Wang","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020061010444475100_gfz031-B4","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1007\/s00018-009-0147-7","article-title":"Hypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing","volume":"66","author":"Webb","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"2020061010444475100_gfz031-B5","doi-asserted-by":"crossref","first-page":"38458","DOI":"10.1074\/jbc.M406026200","article-title":"Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor","volume":"279","author":"Appelhoff","year":"2004","journal-title":"J Biol Chem"},{"key":"2020061010444475100_gfz031-B6","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1242\/jcs.035022","article-title":"HIF at a glance","volume":"22","author":"Brahimi-Horn","year":"2009","journal-title":"J Cell Sci"},{"key":"2020061010444475100_gfz031-B7","doi-asserted-by":"crossref","first-page":"R977","DOI":"10.1152\/ajpregu.00577.2003","article-title":"Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression","volume":"286","author":"Fandrey","year":"2004","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2020061010444475100_gfz031-B8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1042\/BSR20170275","article-title":"Time-dependent inhibition of PHD2","volume":"37","author":"Tcholakov","year":"2017","journal-title":"Biosci Rep"},{"key":"2020061010444475100_gfz031-B9","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1128\/MCB.00161-15","article-title":"Hypoxia signaling cascade for erythropoietin production in hepatocytes","volume":"35","author":"Tojo","year":"2015","journal-title":"Mol Cell Biol"},{"key":"2020061010444475100_gfz031-B10","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1681\/ASN.2010010116","article-title":"Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD","volume":"21","author":"Bernhardt","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2020061010444475100_gfz031-B11","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","article-title":"Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients","volume":"30","author":"Besarab","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2020061010444475100_gfz031-B12","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2020061010444475100_gfz031-B13","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1681\/ASN.2014111139","article-title":"four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia","volume":"27","author":"Holdstock","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2020061010444475100_gfz031-B14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000454818","article-title":"Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects","volume":"45","author":"Akizawa","year":"2017","journal-title":"Am J Nephrol"},{"key":"2020061010444475100_gfz031-B15","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ekir.2018.02.009","article-title":"An exploratory study of daprodustat in erythropoietin-hyporesponsive subjects","volume":"3","author":"Cizman","year":"2018","journal-title":"Kidney Int Rep"},{"key":"2020061010444475100_gfz031-B16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.dmpk.2015.08.004","article-title":"Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects","volume":"30","author":"Hara","year":"2015","journal-title":"Drug Metab Pharmacokinet"},{"key":"2020061010444475100_gfz031-B17","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000464476","article-title":"Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease","volume":"45","author":"Martin","year":"2017","journal-title":"Am J Nephrol"},{"key":"2020061010444475100_gfz031-B18","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ki.2008.295","article-title":"Secondary analysis of the CHOIR trial epoetin-\u03b1 dose and achieved hemoglobin outcomes","volume":"74","author":"Szczech","year":"2008","journal-title":"Kidney Int"},{"key":"2020061010444475100_gfz031-B19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.ajkd.2012.07.014","article-title":"Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis","volume":"61","author":"Koulouridis","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2020061010444475100_gfz031-B20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/ndt\/gfx269","article-title":"Increased mortality in haemodialysis patients administered high doses of erythropoiesis-stimulating agents: a propensity score-matched analysis","volume":"33","author":"P\u00e9rez-Garc\u00eda","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2020061010444475100_gfz031-B21","doi-asserted-by":"crossref","first-page":"20055","DOI":"10.1074\/jbc.272.32.20055","article-title":"Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1","volume":"272","author":"Rolfs","year":"1997","journal-title":"J Biol Chem"},{"key":"2020061010444475100_gfz031-B22","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3324\/haematol.2011.056119","article-title":"Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis","volume":"97","author":"Mastrogiannaki","year":"2012","journal-title":"Haematologica"},{"key":"2020061010444475100_gfz031-B23","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1172\/JCI63924","article-title":"Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis","volume":"122","author":"Liu","year":"2012","journal-title":"J Clin Invest"},{"key":"2020061010444475100_gfz031-B24","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1515\/hsz-2011-0221","article-title":"Matriptase-2 (TMPRSS6) is directly up-regulated by hypoxia inducible factor-1: identification of a hypoxia-responsive element in the TMPRSS6 promoter region","volume":"393","author":"Maurer","year":"2012","journal-title":"Biol Chem"},{"key":"2020061010444475100_gfz031-B25","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.freeradbiomed.2018.07.018","article-title":"An intimate crosstalk between iron homeostasis and oxygen metabolism regulated by the hypoxia-inducible factors (HIFs)","volume":"133","author":"Hirota","year":"2019","journal-title":"Free Radic Biol Med"},{"key":"2020061010444475100_gfz031-B26","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1053\/j.ajkd.2015.11.021","article-title":"A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in ckd: a 28-day, phase 2a randomized trial","volume":"67","author":"Brigandi","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2020061010444475100_gfz031-B27","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s11255-018-1940-8","article-title":"Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis","volume":"50","author":"Xie","year":"2018","journal-title":"Int Urol Nephrol"},{"key":"2020061010444475100_gfz031-B28","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2215\/CJN.06890615","article-title":"Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD","volume":"11","author":"Provenzano","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020061010444475100_gfz031-B29","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","article-title":"Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China","volume":"32","author":"Chen","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2020061010444475100_gfz031-B30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/ndt\/gfy055","article-title":"Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents","volume":"34","author":"Haase","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2020061010444475100_gfz031-B31","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1681\/ASN.2015030241","article-title":"Roxadustat (FG-4592): correction of anemia in incident dialysis patients","volume":"27","author":"Besarab","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2020061010444475100_gfz031-B32","first-page":"405","article-title":"Regulation of hypoxia-inducible factors during inflammation","volume":"435","author":"Frede","year":"2007","journal-title":"Methods Enzymol"},{"key":"2020061010444475100_gfz031-B33","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/nri.2017.103","article-title":"Regulation of immunity and inflammation by hypoxia in immunological niches","volume":"17","author":"Taylor","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"2020061010444475100_gfz031-B34","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1097\/ALN.0b013e31828baa67","article-title":"Hypoxia-inducible factor and target gene expression are decreased in patients with sepsis: prospective observational clinical and cellular studies","volume":"118","author":"Sch\u00e4fer","year":"2013","journal-title":"Anesthesiology"},{"key":"2020061010444475100_gfz031-B35","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.4049\/jimmunol.1103471","article-title":"Loss of the oxygen sensor PHD3 enhances the innate immune response to abdominal sepsis","volume":"189","author":"Kiss","year":"2012","journal-title":"J Immunol"},{"key":"2020061010444475100_gfz031-B36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.exphem.2015.08.010","article-title":"Kynurenine, by activating aryl hydrocarbon receptor, decreases erythropoietin and increases hepcidin production in HepG2 cells: a new mechanism for anemia of inflammation","volume":"44","author":"Eleftheriadis","year":"2016","journal-title":"Exp Hematol"},{"key":"2020061010444475100_gfz031-B37","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.bbrc.2018.09.018","article-title":"Indoxyl glucuronide, a protein-bound uremic toxin, inhibits hypoxia-inducible factor\u2012dependent erythropoietin expression through activation of aryl hydrocarbon receptor","volume":"504","author":"Asai","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"2020061010444475100_gfz031-B38","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bbrc.2015.08.046","article-title":"Expression of hypoxia-inducible factor 1 alpha ameliorate myocardial ischemia in rat","volume":"465","author":"Jianqiang","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"2020061010444475100_gfz031-B39","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacbts.2018.04.005","article-title":"Fatty acids prevent hypoxia-inducible factor-1a signaling through decreased succinate in diabetes","volume":"3","author":"Dodd","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"2020061010444475100_gfz031-B40","doi-asserted-by":"crossref","first-page":"13273","DOI":"10.1038\/s41598-017-13547-1","article-title":"Gene delivery of hypoxia-inducible VEGF targeting collagen effectively improves cardiac function after myocardial infarction","volume":"7","author":"Xia","year":"2017","journal-title":"Sci Rep"},{"key":"2020061010444475100_gfz031-B41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.semnephrol.2018.02.006","article-title":"HIF activation against CVD in CKD: novel treatment opportunities","volume":"38","author":"Tanaka","year":"2018","journal-title":"Semin Nephrol"},{"key":"2020061010444475100_gfz031-B42","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0272-6386(99)70413-0","article-title":"Mechanism of erythropoietin-induced hypertension","volume":"33","author":"Vaziri","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"2020061010444475100_gfz031-B43","doi-asserted-by":"crossref","first-page":"e111838","DOI":"10.1371\/journal.pone.0111838","article-title":"Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects","volume":"9","author":"Flamme","year":"2014","journal-title":"PLoS One"},{"key":"2020061010444475100_gfz031-B44","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1093\/eurheartj\/ehw156","article-title":"Deficiency of the oxygen sensor prolyl hydroxylase 1 attenuates hypercholesterolaemia, atherosclerosis, and hyperglycaemia","volume":"37","author":"Marsch","year":"2016","journal-title":"Eur Heart J"},{"key":"2020061010444475100_gfz031-B45","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.2337\/db14-0472","article-title":"HIF prolyl 4-hydroxylase-2 inhibition improves glucose and lipid metabolism and protects against obesity and metabolic dysfunction","volume":"63","author":"Rahtu-Korpela","year":"2014","journal-title":"Diabetes"},{"key":"2020061010444475100_gfz031-B46","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2215\/CJN.11321017","article-title":"Alteration of HDL protein composition with hemodialysis initiation","volume":"13","author":"Wang","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020061010444475100_gfz031-B47","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/0284186X.2017.1301680","article-title":"HIF-1 in cancer therapy: two decade long story of a transcription factor","volume":"56","author":"Soni","year":"2017","journal-title":"Acta Oncol"},{"key":"2020061010444475100_gfz031-B48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/HP.S130526","article-title":"Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer","volume":"5","author":"Seeley","year":"2017","journal-title":"Hypoxia (Auckl)"},{"key":"2020061010444475100_gfz031-B49","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1161\/CIRCULATIONAHA.116.021494","article-title":"Prolyl-4 hydroxylase 2 (PHD2) deficiency in endothelial cells and hematopoietic cells induces obliterative vascular remodeling and severe pulmonary arterial hypertension in mice and humans through hypoxia-inducible factor-2\u03b1","volume":"133","author":"Dai","year":"2016","journal-title":"Circulation"},{"key":"2020061010444475100_gfz031-B50","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/cpdd.342","article-title":"A randomized, placebo- and positive-controlled, single-dose, crossover thorough QT\/QTc study assessing the effect of daprodustat on cardiac repolarization in healthy subjects","volume":"6","author":"Caltabiano","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2020061010444475100_gfz031-B51","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/21623945.2017.1297346","article-title":"Age-dependent obesity and mitochondrial dysfunction","volume":"6","author":"Li","year":"2017","journal-title":"Adipocyte"},{"key":"2020061010444475100_gfz031-B52","doi-asserted-by":"crossref","first-page":"16568","DOI":"10.1073\/pnas.1308755110","article-title":"HIF1\u03b1 is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis","volume":"110","author":"Miyauchi","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020061010444475100_gfz031-B53","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.cyto.2018.06.022","article-title":"Hypoxia regulates angeogenic-osteogenic coupling process via up-regulating IL-6 and IL-8 in human osteoblastic cells through hypoxia-inducible factor-1\u03b1 pathway","volume":"113","author":"Niu","year":"2018","journal-title":"Cytokine"},{"key":"2020061010444475100_gfz031-B54","doi-asserted-by":"crossref","first-page":"e0168572","DOI":"10.1371\/journal.pone.0168572","article-title":"Hepatocyte hypoxia inducible factor-1 mediates the development of liver fibrosis in a mouse model of nonalcoholic fatty liver disease","volume":"11","author":"Mesarwi","year":"2016","journal-title":"PLoS One"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/35\/6\/926\/33375233\/gfz031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/35\/6\/926\/33375233\/gfz031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T14:53:45Z","timestamp":1591800825000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/35\/6\/926\/5371147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,7]]},"references-count":54,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,3,7]]},"published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfz031","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6]]},"published":{"date-parts":[[2019,3,7]]}}}